Effect of 5-alpha-reductase inhibitor, 4-MAPC, on testicular descent in male rat.

J Urol

Department of Surgery, UCLA School of Medicine, Harbor-UCLA Medical Center, Torrance 90509.

Published: May 1991

Testicular descent has been reported to be a dihydrotestosterone (DHT) dependent event. To further elucidate the role of DHT in the process of testicular descent, a group of rats were treated with the 5-alpha reductase inhibitor, 4-MAPC, from birth to day 28 of age and the incidence of testicular descent as well as ventral prostate weight was noted at day 29 of age. It was determined that in the doses used, 4-MAPC failed to prevent testicular descent. Because 4-MAPC inhibited ventral prostate weight by only 53% (as compared to a 75% inhibition by castration), the failure of the 4-MAPC to prevent testicular descent could be due to its inability to completely inhibit tissue 5-alpha reductase activity. The results of this study do not mitigate against the role of other nonhormonal factors working in tandem with DHT in the induction of testicular descent in this animal model.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0022-5347(17)38542-7DOI Listing

Publication Analysis

Top Keywords

testicular descent
28
inhibitor 4-mapc
8
5-alpha reductase
8
day age
8
ventral prostate
8
prostate weight
8
prevent testicular
8
testicular
7
descent
7
4-mapc
5

Similar Publications

The hormonal aspect of undescended testes (UDTs) in prepubertal boys, i.e., after mini-puberty, is poorly understood.

View Article and Find Full Text PDF
Article Synopsis
  • Cryptorchidism can lead to infertility and testicular cancer, with estrogen signaling being essential for testicle descent and hormonal imbalances contributing to the condition.
  • The study aimed to examine the association between specific genetic variations (polymorphisms) in the CYP19 and ESR2 genes and the risk of developing cryptorchidism in children.
  • Results showed significant differences in the frequency of certain genotypes and alleles between cryptorchid patients and healthy controls, suggesting that specific variations could increase the risk of cryptorchidism while others may provide protection.
View Article and Find Full Text PDF

Context: Congenital hypogonadotropic hypogonadism (CHH) is defined as an isolated deficiency of gonadotropin hormones. Mini-puberty, a transient postnatal activation of the hypothalamic-pituitary-gonadal axis in healthy infants, provides a window of opportunity to diagnose and treat CHH. Currently, in male infants with CHH, testosterone is used to increase phallus size.

View Article and Find Full Text PDF

Introduction: Bilateral testicular tumours occur in 3-5% of all cases with testicular neoplasms. In the majority of cases, histology of the two new growths is identical. The time interval between the two neoplastic events rarely exceeds 10 years.

View Article and Find Full Text PDF

Exploring Testicular Descent: Recent Findings and Future Prospects in Canine Cryptorchidism.

Sex Dev

November 2024

Department of Ribonucleoprotein Biochemistry, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.

Background: Canine cryptorchidism, manifested by an abnormal testicular position, poses significant health risks and reproductive challenges in affected males. Despite a high prevalence, estimated at up to 10% in the canine population, a comprehensive understanding of its pathogenesis remains elusive. Studies in human cryptorchids and knockout mice have identified key factors involved in testicular descent, including INSL3, RXFP2, and AR.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!